Bicara Therapeutics

Bicara Therapeutics is an advanced-stage organization developing pioneering biologics designed to unite the precision of targeted therapy and the strength of immunotherapy. The company's dual-function biologics aim to transport an immunomodulatory payload directly to the tumor microenvironment to enhance immune cell activity, potentially providing enduring effectiveness. Just as the company combines two modalities in its bifunctional therapies, it also unites two continents with a team in Cambridge, Mass. and a dedicated research arm, supported by Biocon, in Bangalore, India.. Biora Therapeutics, Inc. is the biotech company reimagining therapeutic delivery. By inventing innovative intelligent capsules tailored for targeted drug delivery to the GI tract and systemic, non-invasive delivery of biotherapeutics, Biora is developing treatments to enhance the lives of patients. The company was established in 2010 as Ascendant MDx, Inc., and changed its name to Progenity, Inc. in 2013. Its initial public offering was on June 19, 2020. In 2021, the company went through a strategic revamp to concentrate on its innovative therapeutics pipeline, and in 2022 it rebranded as Biora Therapeutics, Inc.. InCarda Therapeutics, Inc. is a privately-held, advanced-stage biopharmaceutical company pioneering a unique approach to treating cardiovascular conditions through inhalation. The advantage of inhalation is that it administers medicine in the